78491-02-8
CAS 78491-02-8
78491-02-8 (CAS 78491-02-8) is a pharmaceutical compound with 0 bioactivity targets and 1 adverse event association.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Drug abuse | 38 | 133.946 | 10013654 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| N-(1,3-BIS(HYDROXYMETHYL)-2,5-DIOXO-4-IMIDAZOLIDINYL)-N,N'-BIS(HYDROXYMETHYL)UREA | 1990423 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 78491-02-8 used for in pharmaceutical contexts?
78491-02-8 (CAS 78491-02-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 78491-02-8?
78491-02-8 has 1 DrugCentral/FAERS adverse event association. Rendered reaction terms include Drug abuse. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 78491-02-8 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Diazolidinyl Urea with EU status "restricted".
What clinical phase is 78491-02-8 in?
No phase 1-4 clinical development badge is rendered for 78491-02-8 because the matched compound identifier rows do not contain a max-phase value.